352 related articles for article (PubMed ID: 25188479)
1. Comparative mechanisms of action of proteasome inhibitors.
Wang M
Oncology (Williston Park); 2011 Nov; 25 Suppl 2():19-24. PubMed ID: 25188479
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibitors.
Teicher BA; Tomaszewski JE
Biochem Pharmacol; 2015 Jul; 96(1):1-9. PubMed ID: 25935605
[TBL] [Abstract][Full Text] [Related]
3. Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
Besse A; Besse L; Kraus M; Mendez-Lopez M; Bader J; Xin BT; de Bruin G; Maurits E; Overkleeft HS; Driessen C
Cell Chem Biol; 2019 Mar; 26(3):340-351.e3. PubMed ID: 30612952
[TBL] [Abstract][Full Text] [Related]
4. New proteasome inhibitors in myeloma.
Lawasut P; Chauhan D; Laubach J; Hayes C; Fabre C; Maglio M; Mitsiades C; Hideshima T; Anderson KC; Richardson PG
Curr Hematol Malig Rep; 2012 Dec; 7(4):258-66. PubMed ID: 23065395
[TBL] [Abstract][Full Text] [Related]
5. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
[TBL] [Abstract][Full Text] [Related]
6. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
7. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
Thompson JL
Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibitors in the treatment of multiple myeloma.
McBride A; Ryan PY
Expert Rev Anticancer Ther; 2013 Mar; 13(3):339-58. PubMed ID: 23477520
[TBL] [Abstract][Full Text] [Related]
9. Insulin-Degrading Enzyme Is a Non Proteasomal Target of Carfilzomib and Affects the 20S Proteasome Inhibition by the Drug.
Tundo GR; Sbardella D; Oddone F; Grasso G; Marini S; Atzori MG; Santoro AM; Milardi D; Bellia F; Macari G; Graziani G; Polticelli F; Cascio P; Parravano M; Coletta M
Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204815
[TBL] [Abstract][Full Text] [Related]
10. Safety of proteasome inhibitors for treatment of multiple myeloma.
Schlafer D; Shah KS; Panjic EH; Lonial S
Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
[TBL] [Abstract][Full Text] [Related]
11. Discovery and development of second-generation proteasome inhibitors.
Kirk CJ
Semin Hematol; 2012 Jul; 49(3):207-14. PubMed ID: 22726543
[TBL] [Abstract][Full Text] [Related]
12. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
Hurchla MA; Garcia-Gomez A; Hornick MC; Ocio EM; Li A; Blanco JF; Collins L; Kirk CJ; Piwnica-Worms D; Vij R; Tomasson MH; Pandiella A; San Miguel JF; Garayoa M; Weilbaecher KN
Leukemia; 2013 Feb; 27(2):430-40. PubMed ID: 22763387
[TBL] [Abstract][Full Text] [Related]
13. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs).
Kuhn DJ; Orlowski RZ; Bjorklund CC
Curr Cancer Drug Targets; 2011 Mar; 11(3):285-95. PubMed ID: 21247387
[TBL] [Abstract][Full Text] [Related]
14. Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
Lonial S; Boise LH
Oncology (Williston Park); 2011 Nov; 25 Suppl 2():25-31. PubMed ID: 25188480
[TBL] [Abstract][Full Text] [Related]
15. Carfilzomib: a novel agent for multiple myeloma.
Redic K
J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
[TBL] [Abstract][Full Text] [Related]
16. High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS.
Romaniuk W; Bolkun L; Kalita J; Galar M; Bernatowicz M; Ostrowska H; Kloczko J
Ann Hematol; 2018 Oct; 97(10):1879-1887. PubMed ID: 29946907
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines.
Dettmer S; Theile D; Schäfer J; Seckinger A; Burhenne J; Weiss J
Naunyn Schmiedebergs Arch Pharmacol; 2016 Oct; 389(10):1091-101. PubMed ID: 27422413
[TBL] [Abstract][Full Text] [Related]
18. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
19. Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs.
Hasinoff BB; Patel D
Cardiovasc Toxicol; 2018 Dec; 18(6):557-568. PubMed ID: 29951728
[TBL] [Abstract][Full Text] [Related]
20. Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
Pierce MR; Robinson RM; Ibarra-Rivera TR; Pirrung MC; Dolloff NG; Bachmann AS
Leuk Res; 2020 Jan; 88():106271. PubMed ID: 31778912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
